Home Understanding Acromegaly Understanding Acromegaly
What Causes Acromegaly
Symptoms of Acromegaly
How is Acromegaly Diagnosed
Treatment options for Acromegaly About Somatuline® Depot (lanreotide) Injection About Somatuline® Depot (lanreotide) Injection
What is Somatuline® Depot (lanreotide) Injection
Who should take Somatuline® Depot (lanreotide) Injection?
Talking to Your Healthcare Professional
How does Somatuline® Depot (lanreotide) Injection Work?
How to take Somatuline® Depot (lanreotide) Injection?
How long should I take Somatuline® Depot (lanreotide) Injection?
Possible Side Effects Patient Resources Patient Resources
Reimbursement for Somatuline® Depot (lanreotide) Injection
Resources for Information and Support
Glossary Full Prescribing Information
to health care professionals
Somatuline Depot coupon
 

View our injection video

Somatuline® Depot (lanreotide) Injection is injected in an easy, two-step injection process. Learn more about how easy it is to inject Somatuline® Depot (lanreotide) Injection.

 
Talk to health care professional
Sign Up for Updates
Full Prescribing Information

View the Full Prescribing Information for Somatuline® Depot (lanreotide) Injection.

You must have Adobe Acrobat Reader to view these files. If you do not have Adobe Acrobat Reader installed on your computer, you can download it for free.

ADOBE Get Acrobat Reader

Adobe®, the Adobe logo, Acrobat®, and the Acrobat logo are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

IMPORTANT SAFETY INFORMATION


Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline® Depot (lanreotide) Injection may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

Home | Full Prescribing Information | Privacy Policy | Site User Guide | Sitemap | Legal Notices | Privacy Statement
w

SOMATULINE® DEPOT (LANREOTIDE) INJECTION IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

THIS WEB SITE IS INTENDED FOR US RESIDENTS ONLY. TERCICA, INC. ALL RIGHTS RESERVED.

2008 Tercica Legal Notices | Privacy Statement